




Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid

The effect of *Helicobacter pylori* infection on growth velocity in young children from poor urban communities in Ecuador

Andrey I. Egorov^{a,b,*}, Fernando Sempértegui^{b,c,d}, Bertha Estrella^{b,c,d}, Josefina Egas^{c,e}, Elena N. Naumova^{b,f}, Jeffrey K. Griffiths^{b,f}

^a US Environmental Protection Agency, National Center for Environmental Assessment, 26 W. Martin Luther King Drive, MS A110, Cincinnati, OH 45268, USA

^b Tufts School of Medicine, Department of Public Health and Family Medicine, Boston, Massachusetts, USA

^c Corporación Ecuatoriana de Biotecnología, Quito, Ecuador

^d Facultad de Medicina, Universidad Central del Ecuador, Quito, Ecuador

^e Escuela de Bioanálisis, Pontificia Universidad Católica del Ecuador, Quito, Ecuador

^f Tufts University Friedman School of Nutrition Science and Policy, Boston, Massachusetts, USA

ARTICLE INFO

Article history:

Received 11 December 2009

Accepted 8 March 2010

Corresponding Editor: William Cameron, Ottawa, Canada

Keywords:

Helicobacter pylori
Growth velocity
Children
Fecal antigen
IgG antibody
Ecuador

SUMMARY

Objective: To characterize the potential effects of *Helicobacter* infections on growth velocity in low socioeconomic status young children in a developing country.

Methods: Children were recruited in poor suburbs of Quito, Ecuador. Normally nourished, mildly and substantially malnourished children (defined using weight-for-age Z-scores at recruitment) formed equal strata. Six height and weight measurements were collected during one year. Enrollment and exit serum samples were analyzed for anti-*Helicobacter* IgG and exit non-diarrheal feces tested for *Helicobacter* antigen.

Results: Among 124 participants (enrollment age 19 ± 9 months), 76 (61%) excreted fecal antigen at exit (were infected). Of these, 44 were seropositive at least once (chronic infections) and 32 tested seronegative both times (new or acute phase infections). The adjusted linear growth velocity during follow-up in children with new infections was reduced by 9.7 (3.8, 15.6) mm/year compared to uninfected controls and 6.4 (0.0, 12.9) mm/year compared to children with chronic infections. The effects of *Helicobacter* infections on ponderal growth were not significant.

Conclusion: These results suggest that linear growth velocity is reduced in young children during the initial phase of *Helicobacter* infection.

Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

1. Introduction

Helicobacter pylori is an important pathogen that can cause gastritis, gastric and duodenal ulcers, and gastric cancer.¹ This bacterium is uniquely adapted to chronically infect the human stomach. It elicits a predominantly Th1-type immune response, which may be responsible for gastritis symptoms.^{2,3} Infections typically spread through person-to-person contacts,² but water-borne transmission may also occur.⁴ In developing countries, most people acquire infection in early childhood.^{2,5} The acquisition of infection is often followed by transient acute gastritis symptoms and depressed gastric acid secretion.^{2,6,7} *Helicobacter* has been shown to impair absorption of nutrients and vitamins,^{8,9} and retard growth in children in developing countries.^{6,10–13}

Helicobacter-infected individuals excrete *Helicobacter* antigen. Fecal antigen tests have excellent sensitivity and specificity as

compared to more invasive diagnostic tests in children.^{14–18} *Helicobacter* infection also induces strong antibody responses.¹⁹ Animal experiments have demonstrated that the development of an antibody response reduces gastritis symptoms.²⁰ In humans, IgG seroconversion occurs several months post-infection.^{21,22} This time lag between infection and IgG seroconversion has been utilized to define acute (prior to seroconversion) and chronic (after seroconversion) phases of infection.^{23–25} Antibodies also persist following spontaneous eradication of *Helicobacter*, which sometimes occurs in children.²⁶

The objective of this study was to evaluate the effects of both chronic and acute *H. pylori* infections on linear and ponderal growth in young Ecuadorian children.

2. Methods

This prospective study was nested within a larger study of the effects of micronutrient (vitamin A and/or zinc) supplementation in young children (manuscript in review). The parent study was

* Corresponding author. Tel.: +1 513 407 5491.

E-mail address: andrey.egorov@tufts.edu (A.I. Egorov).

registered at www.ClinicalTrials.gov (NCT00228254). For that parent study, children aged 6 to 36 months were recruited in poor suburbs of Quito, Ecuador at community recruitment sessions in April–May 2002 and 2003. Weight-for-age and height-for-age standard deviation scores or Z-scores (WAZ and HAZ) were estimated using the US National Center for Health Statistics reference data. Malnourished children were intentionally over-sampled: substantially malnourished ($WAZ \leq -2$), mildly malnourished ($-2 < WAZ \leq -1$), and normally nourished children ($WAZ > -1$) formed one-third each of the study population. Severely malnourished children (weight < 60% of the age-adjusted norm) were excluded from the study and referred to nutritional rehabilitation centers. After recruitment, children were randomly assigned into intervention or placebo groups, and followed for approximately one year starting from June. This manuscript presents data collected from the placebo group.

A household survey was conducted at enrollment to assess demographic, socioeconomic, and hygiene characteristics. Study nurses visited all children during follow-up four times per week to look for respiratory and diarrheal symptoms. Growth parameters were measured at enrollment and approximately every 10 weeks thereafter for a total of six measurements per child. Blood samples were collected from each child after overnight fasting at enrollment and exit to measure micronutrient levels.

All aspects of this nested study were approved by the ethics committees of Tufts University School of Medicine in Boston and the Corporación Ecuatoriana de Biotecnología in Quito. Separate informed consents were obtained from parents or guardians of each participating child for the parent study and nested study.

Leftover serum samples were analyzed for anti-Helicobacter IgG responses using commercial ELISA test kits procured from IBL Immuno-Biological Laboratories (Hamburg, Germany). These kits included a microplate coated with a mixture of purified bacterial proteins containing CagA and VacA antigens, secondary horseradish peroxidase-conjugated anti-human antibody solution, and a set of standards. The optical density values for anti-Helicobacter IgG responses were converted into arbitrary unit concentrations (U/ml) and dichotomized using microplate-specific cut-off values. At the end of the follow-up (study exit), the participants of this nested study also provided one non-diarrheal fecal sample, which was analyzed for excreted Helicobacter antigen using a sandwich monoclonal antibody-based ELISA assay (Hp StAR™, DAKO A/S, Glostrup, Denmark). The Helicobacter fecal test results were dichotomized at the optical density value of 0.15 as per the manufacturer's instructions. All laboratory tests were conducted at the Catholic University of Ecuador (Pontificia Universidad Católica del Ecuador) in Quito. Samples were collected from households by

study nurses, delivered to the laboratory in refrigerated containers, and stored at -20°C until analysis.

Children were classified as infected or non-infected based on the results of their fecal antigen test. Infected children were further classified based on their serology as having (1) chronic infections (tested seropositive at enrollment and/or exit) or (2) new or acute phase infections (tested seronegative both times).

Data were analyzed using SAS v. 9.2 (SAS Institute, Cary, NC, USA). Demographic and socioeconomic risk factors for Helicobacter infection were analyzed using logistic regression. Data on growth during follow-up were analyzed using mixed effect regression models using SAS procedure GLIMMIX.

3. Results

Only children from the placebo group who submitted their non-diarrheal fecal samples at the study exit were included in this analysis ($N = 124$). Of these, 26 children represented the 2002–2003 cohort of the parent study and 98 children represented the 2003–2004 cohort (20% and 71%, respectively, of the placebo arm of each cohort). The breakdown of the study population by gender, nutritional status strata, and Helicobacter infection status is presented in Table 1.

The age at enrollment ranged from 4.6 to 35.7 months, average \pm standard deviation 19.0 ± 8.5 months. The average duration of follow-up (interval between the first and the last anthropometric measurement) was 388 days, standard deviation 26 days, range 277–413 days. The average age at study exit was 31.8 months. Normally nourished children were, on average, younger than substantially malnourished children, while children who were not infected and children who had acute phase infections were, on average, younger than children with chronic phase infections (Table 1).

Seventy-six (61%) study participants were infected with *H. pylori* (excreted antigen) at study exit (acute and chronic infections combined). A detailed breakdown of the study population by infection status and serology is presented in Table 2. Among 44 children who were classified as chronically infected, 41 (93%) were seropositive at exit. Among 48 children who were not infected with Helicobacter, only four (8%) were seropositive at exit.

Prevalence rates of Helicobacter infection at study exit were 73% in substantially malnourished, 47% in mildly malnourished, and 67% in normally nourished children. Although the odds of infection in mildly malnourished children were significantly smaller than in normally nourished controls ($p = 0.03$), the inconsistent pattern with greater odds of infection in substantially malnourished children suggests that this observed association was due to a random effect. Crowded living conditions (three or more

Table 1
Descriptive statistics of the study population

| Factor | n (%) of participants | Mean (SD) age at enrollment, months | Mean (SD) height at enrollment, mm | Mean (SD) height-for-age Z-score at enrollment | Mean (SD) linear growth velocity, mm/year | Mean (SD) ponderal growth velocity, kg/year |
|----------------------------|-----------------------|-------------------------------------|------------------------------------|--|---|---|
| All participants | 124 (100) | 19.0 (8.5) | 758 (82) | -1.77 (1.04) | 97 (22) | 2.17 (0.88) |
| Gender | | | | | | |
| Boys | 73 (58.9) | 19.3 (8.4) | 766 (78) | -1.82 (1.13) | 94 (22) | 2.13 (1.09) |
| Girls | 51 (41.1) | 18.7 (8.6) | 747 (86) | -1.71 (0.90) | 99 (27) | 2.18 (0.53) |
| Nutritional status | | | | | | |
| Substantially malnourished | 37 (29.8) | 20.3 (8.1) | 750 (68) | -2.44 (0.69) | 92 (21) | 2.15 (0.70) |
| Mildly malnourished | 45 (36.3) | 19.9 (7.6) | 767 (70) | -1.87 (0.84) | 92 (21) | 2.19 (1.23) |
| Normally nourished | 42 (33.9) | 16.9 (9.4) | 756 (103) | -1.08 (1.06) | 103 (28) | 2.10 (0.59) |
| <i>H. pylori</i> infection | | | | | | |
| New infection | 32 (25.8) | 18.3 (8.2) | 753 (84) | -1.87 (1.19) | 92 (24) | 2.08 (0.53) |
| Chronic infection | 44 (35.5) | 20.6 (8.8) | 766 (76) | -1.90 (1.00) | 94 (25) | 2.09 (0.49) |
| Not infected | 48 (38.7) | 18.1 (8.3) | 755 (86) | -1.59 (0.95) | 100 (24) | 2.25 (1.30) |

SD, standard deviation.

Table 2
Detailed breakdown of the study population by infection status and serology

| Infection status category | Fecal antigen test | Serum test at enrollment | Serum test at exit | n | % of children in infection status category |
|---------------------------|-----------------------|--------------------------|--------------------|----|--|
| Acute phase | Positive | Negative | Negative | 32 | 100% |
| Chronic phase | Positive | Positive | Negative | 3 | 7% |
| | Positive | Negative | Positive | 19 | 43% |
| Not infected | Positive | Positive | Positive | 22 | 50% |
| | Subtotal for category | | | 44 | 100% |
| | Negative | Negative | Negative | 36 | 75% |
| | Negative | Positive | Negative | 8 | 17% |
| | Negative | Negative | Positive | 3 | 6% |
| Not infected | Negative | Positive | Positive | 1 | 2% |
| | Subtotal for category | | | 48 | 100% |

people per room) was the only socioeconomic indicator associated with *Helicobacter* infection (positive fecal test) in logistic regression analysis: odds ratio 2.67 (95% confidence interval (CI) 1.04, 6.91; $p = 0.04$), adjusting for nutritional status strata and age.

Preliminary mixed effect regression analysis at the model development stage demonstrated that adjusted growth velocities during follow-up were similar in all three nutritional status strata. Therefore, interaction terms between nutritional status and time were not included in the final model. Episodes of diarrhea or respiratory illness during follow-up, as well as crowded living conditions, were not significantly associated with growth velocity. Therefore, these variables were also not included in the final model. Height at enrollment and growth velocity in children who tested seropositive at least once but had negative fecal antigen test at exit (eradicated *Helicobacter* infection) did not differ significantly or substantially from those in children who had all fecal and serological tests negative ($p > 0.5$ for both tests). This confirmed that including all fecal test-negative children in the control group irrespective of their serological status was appropriate.

The final mixed effect model for linear growth included random effects for intercept, age, and age squared. The main effects are presented in Table 3. The non-linear effect of age on linear growth was modeled using a cubic polynomial. Indicator variables for gender and nutritional status strata were used to model the effects of these parameters on height at enrollment. Girls were significantly shorter and lighter than boys; substantially malnourished and mildly malnourished children were significantly shorter and lighter than normally nourished children.

The predicted average linear growth velocity in children who were 19 months old at enrollment (average age of the participants) and remained free of *Helicobacter* infections (all tests negative)

was 96 mm/year. To model the effects of *Helicobacter* infections on growth velocity, the regression model contained two interaction terms between indicator variables for new and chronic *Helicobacter* infections and continuous variable for time from enrollment. Age-adjusted growth velocity during follow-up was reduced in children with new *Helicobacter* infections by 9.7 (95% CI 3.8, 15.6) mm/year compared to controls, while the effect of chronic infections was weak and non-significant (Table 3). Further analysis (not shown in Table 3) demonstrated that age-adjusted growth velocity in infected seronegative children (new infections) was reduced by 6.4 (95% CI 0.0, 12.9) mm/year ($p = 0.05$) compared to infected seropositive children (chronic infections). In stratified regression analysis, the adjusted detrimental effects of new *Helicobacter* infections on growth velocity were very similar in boys and girls, 10.5 (95% CI -0.9, 21.9) mm/year and 9.0 (95% CI -2.2, 20.1) mm/year, respectively.

The effects of *Helicobacter* on ponderal growth were analyzed using similar mixed effect regression models (except the effect of age was modeled using a quadratic polynomial). The adjusted detrimental effects of new and chronic *Helicobacter* infections on ponderal growth velocity were small and not significant, 53 (95% CI -147, 253) g/year ($p = 0.6$) and 10 (95% CI -173, 193) g/year ($p = 0.9$), respectively.

4. Discussion

The main finding of this study was that new *Helicobacter* infections defined as positive fecal antigen test and negative serology were associated with reduced linear growth in young children. The estimated deficit in the average growth velocity during one year of follow-up in children with new infections compared to non-infected controls was almost 10 mm/year, which translates into approximately 10% slower linear growth. There was no evidence of catch-up growth in children with chronic *Helicobacter* infection. These results show that *Helicobacter* infections contributed substantially to the pronounced growth deficit in young Ecuadorian children from poor urban neighborhoods.

The finding of this study is in agreement with previous research in Colombia that also demonstrated the detrimental effect of *Helicobacter* infection on growth being most pronounced right after the infection.¹³ It could be speculated that chronic infection is associated with a different pattern of gastric inflammation which does not cause a detrimental effect on growth in children. IgG seroconversion, which occurs several months post-infection in children, can serve as a biomarker of the transition to the chronic phase of infection. Akhiani et al.²⁰ demonstrated that the development of an anti-*Helicobacter* antibody response is associated with reduced gastric inflammation but enhanced colonization in animal models and speculated that anti-*Helicobacter* antibody may facilitate the persistence of this pathogen.

Table 3
Results of linear mixed effect regression analysis of the effects of *Helicobacter pylori* infections on linear growth in Ecuadorian children

| Variable | Effect estimate (95% CI) | p-Value |
|--|--------------------------|---------|
| Age (years) | 187.0 (168.0, 206.0) | <0.0001 |
| Age ² | -32.2 (-41.5, -22.9) | <0.0001 |
| Age ³ | 3.2 (1.8, 4.7) | <0.0001 |
| Gender | | |
| Male | 13.4 (4.4, 22.3) | 0.004 |
| Female | 0 | - |
| Nutritional status strata | | |
| Substantially malnourished | -44.1 (-55.2, -33.0) | <0.0001 |
| Mildly malnourished | -27.4 (-38.0, -16.9) | <0.0001 |
| Normally malnourished | 0 | - |
| <i>H. pylori</i> infection* time from enrollment | | |
| New infection | -9.7 (-15.6, -3.8) | 0.001 |
| Chronic infection | -3.3 (-8.7, 2.2) | 0.2 |
| Not infected | 0 | - |

CI, confidence interval.

The detrimental effect of new *Helicobacter* infection on linear growth velocity in these Ecuadorian children was almost twice the 5 mm/year effect previously observed in Colombian children.¹¹ This discrepancy may be explained by different source populations and, at least in part, a random sampling effect. The effect of *Helicobacter* on ponderal growth in these Ecuadorian children was small and non-significant, which is consistent with the results of previous research in Colombia.^{11,13}

This study used a monoclonal fecal antigen ELISA test to detect *Helicobacter* infections and serological IgG ELISA tests to further classify infections as new (negative serology) or chronic (positive serology) using a previously developed infection classification scheme.^{22–24} It has been demonstrated previously that the Hp StAR™ monoclonal antibody ELISA test for fecal *Helicobacter* antigen can be used as a reliable indicator of *Helicobacter* infection in children because it compares very well with invasive diagnostic tests as well as the ¹³C-urea breath test, with sensitivity ranging from 94.4% to 98.2% and specificity from 94.7% to 98.1%, depending on the study.^{14,15,17}

The 61% prevalence rate of *Helicobacter* infections in these Ecuadorian children as determined by the Hp StAR™ fecal antigen test is similar to the 53% prevalence rate in 2-year-old Colombian children as determined by the ¹³C-urea breath test,⁵ but higher than the 23% prevalence rate reported in another group of Colombian children who were, on average, approximately 4 years of age.¹¹

A limitation of this study was the lack of fecal *Helicobacter* antigen testing at enrollment. This did not allow a more accurate assessment of the timing of *Helicobacter* infection and duration of its effects on growth. Moreover, severe episodes of diarrhea in study participants were treated with antibiotics, altering the natural history of the episode. Therefore, the lack of association between episodes of diarrhea and growth may not be generalizable to the source population of low socioeconomic status Ecuadorian children. Strengths of this study include the collection of detailed growth data and the use of a socioeconomically homogeneous source population. The results of this study provide further evidence of detrimental developmental effects of *Helicobacter* in young children living in poor economic conditions.

Conflict of interest

No conflict of interest to declare.

Ethical approval

All aspects of this study were approved by the ethics committees of Tufts University School of Medicine in Boston, MA and the Corporación Ecuatoriana de Biotecnología in Quito, Ecuador.

Acknowledgements

This study was funded by the National Institutes of Health (R01 HD38327 “Vitamin A and Zinc: Prevention of Pneumonia” Study Supplement 2 to JKG). The preparation of this paper was funded in part by the US Environmental Protection Agency. The study sponsors had no role in the study design, collection, analysis and interpretation of data. Although this manuscript was reviewed and cleared for publication by the US Environmental Protection Agency following standard procedures, the views expressed in this article are those of the authors; they do not necessarily reflect the views or policies of the US Environmental Protection Agency. Mention of

trade names or commercial products does not constitute endorsement or recommendation for use.

References

- Lee A. *Helicobacter pylori*: the unsuspected and unlikely global gastroduodenal pathogen. *Int J Infect Dis* 1996;**1**:47–56.
- Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002;**347**:1175–86.
- Lohoff M, Rollinghoff M, Sommer F. *Helicobacter pylori* gastritis: a Th1 mediated disease? *J Biotechnol* 2000;**83**:33–6.
- Bellaack NR, Koehoorn MW, MacNab YC, Morshed MG. A conceptual model of water's role as a reservoir in *Helicobacter pylori* transmission: a review of the evidence. *Epidemiol Infect* 2006;**134**:439–49.
- Goodman KJ, Correa P, Tenganá Aux HJ, Ramírez H, DeLany JP, Guerrero Pepinosa O, et al. *Helicobacter pylori* infection in the Colombian Andes: a population-based study of transmission pathways. *Am J Epidemiol* 1996;**144**:290–9.
- Dale A, Thomas JE, Darboe MK, Coward WA, Harding M, Weaver LT. *Helicobacter pylori* infection, gastric acid secretion, and infant growth. *J Pediatr Gastroenterol Nutr* 1998;**26**:393–7.
- Graham DY, Opekun AR, Osato MS, El-Zimaity HM, Lee CK, Yamaoka Y, et al. Challenge model for *Helicobacter pylori* infection in human volunteers. *Gut* 2004;**53**:1235–43.
- Annibale B, Capurso G, Delle FG. Consequences of *Helicobacter pylori* infection on the absorption of micronutrients. *Dig Liver Dis* 2002;**34**:S72–7.
- Ciacchi C, Sabbatini F, Cavallaro R, Castiglione F, Di Bella S, Iovino P, et al. *Helicobacter pylori* impairs iron absorption in infected individuals. *Dig Liver Dis* 2004;**36**:455–60.
- Passaro DJ, Taylor DN, Gilman RH, Cabrera L, Parsonnet J. Growth slowing after acute *Helicobacter pylori* infection is age-dependent. *J Pediatr Gastroenterol Nutr* 2002;**35**:522–36.
- Bravo LE, Mera R, Reina JC, Pradilla A, Alzate A, Fonham E, et al. Impact of *Helicobacter pylori* infection on growth of children: a prospective cohort study. *J Pediatr Gastroenterol Nutr* 2003;**37**:614–9.
- Thomas JE, Dale A, Bunn JE, Harding M, Coward WA, Cole TJ, et al. Early *Helicobacter pylori* colonisation: the association with growth faltering in The Gambia. *Arch Dis Child* 2004;**89**:1149–54.
- Mera RM, Correa P, Fonham EE, Reina JC, Pradilla A, Alzate A, et al. Effects of a new *Helicobacter pylori* infection on height and weight in Colombian children. *Ann Epidemiol* 2006;**16**:347–51.
- Makrithatis A, Barousch W, Pasching E, Binder C, Kuderna C, Apfalter P, et al. Two enzyme immunoassays and PCR for detection of *Helicobacter pylori* in stool specimens from pediatric patients before and after eradication therapy. *J Clin Microbiol* 2000;**38**:3710–4.
- Koletzko S, Konstantopoulos N, Bosman D, Feydt-Schmidt A, van der Ende A, Kalach N, et al. Evaluation of a novel monoclonal enzyme immunoassay for detection of *Helicobacter pylori* antigen in stool from children. *Gut* 2003;**52**:804–6.
- de Carvalho Costa Cardinali L, Rocha GA, Rocha AM, de Moura SB, de Figueiredo Soares T, Esteves AM, et al. Evaluation of [¹³C]urea breath test and *Helicobacter pylori* stool antigen test for diagnosis of *H. pylori* infection in children from a developing country. *J Clin Microbiol* 2003;**41**:3334–5.
- Hino B, Eliakim R, Levine A, Sprecher H, Berkowitz D, Hartman C, et al. Comparison of invasive and non-invasive tests diagnosis and monitoring of *Helicobacter pylori* infection in children. *J Pediatr Gastroenterol Nutr* 2004;**39**:519–23.
- Dondi E, Rapa A, Boldorini R, Fonio P, Zanetta S, Oderda G. High accuracy of noninvasive tests to diagnose *Helicobacter pylori* infection in very young children. *J Pediatr* 2006;**149**:817–21.
- Mattsson A, Tinnert A, Hamlet A, Lonroth H, Bolin I, Svennerholm AM. Specific antibodies in sera and gastric aspirates of symptomatic and asymptomatic *Helicobacter pylori*-infected subjects. *Clin Diagn Lab Immunol* 1998;**5**:288–93.
- Akhiani AA, Schön K, Franzén LE, Pappo J, Lycke N. *Helicobacter pylori*-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. *J Immunol* 2004;**172**:5024–33.
- Thomas JE, Dale A, Harding M, Coward WA, Cole TJ, Weaver LT. *Helicobacter pylori* colonization in early life. *Pediatr Res* 1999;**45**:218–23.
- Nurgalieva ZZ, Opekun AR, Graham DY. Problem of distinguishing false-positive tests from acute or transient *Helicobacter pylori* infections. *Helicobacter* 2006;**11**:69–74.
- Graham DY. Community acquired acute *Helicobacter pylori* gastritis. *J Gastroenterol Hepatol* 2000;**15**:1353–5.
- Opekun AR, Gilger MA, Denyes SM, Nirken MH, Philip SP, Osato MS, et al. *Helicobacter pylori* infection in children of Texas. *J Pediatr Gastroenterol Nutr* 2000;**31**:405–10.
- Nurgalieva ZZ, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB, et al. B-cell and T-cell immune responses to experimental *Helicobacter pylori* infection in humans. *Infect Immun* 2005;**73**:2999–3006.
- Perri F, Pastore M, Clemente R, Festa V, Quitadamo M, Niro G, et al. *Helicobacter pylori* infection may undergo spontaneous eradication in children: a 2-year follow-up study. *J Pediatr Gastroenterol Nutr* 1998;**27**:181–3.